Blueprint Medicines Corporation (BPMC) — Institutional Holders & Catalysts

Fund Holdings

6 fund convergence

Avoro Capital Advisors

Casdin Capital

Driehaus Capital

Baker Bros. Advisors

Rock Springs Capital

Eventide Asset Management

AI Signal

Signal Note: Avoro Exit from BPMC

Avoro's complete exit of 375K shares ($48.1M) from Blueprint Medicines warrants scrutiny, though the 6-fund specialist holder convergence (Baker Bros., Casdin, Driehaus, Eventide, Rock Springs) suggests institutional conviction remains intact around the core portfolio—likely AYVAKIT (avapritinib) in advanced systemic mastocytosis and potentially GAVRETO (pralsetinib) expansion. The exit timing should be cross-referenced against recent clinical readouts, competitive dynamics in kinase inhibitor space, or capital allocation shifts at Avoro rather than interpreted as fundamental concern given the robust specialist fund consensus.

Unlock full AI analysis — 7-day free trial

2 quarters

Position Trend

Nov 14, 2025

0 funds

Feb 13, 2026

0 funds

Feb 17, 2026

0 funds

Mar 16, 2026

0 funds

-100% total institutional value over 6 quarters

Position Details

Avoro Capital AdvisorsEXITMar 16, 2026

Shares: 0Value: N/A

Casdin CapitalEXITFeb 17, 2026

Shares: 0Value: N/A

+ 21more — see how much conviction went in

See the Full Story

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

Blueprint Medicines Corporation

Fund Holdings

Position Trend

Catalysts

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links